221 related articles for article (PubMed ID: 32921305)
1. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study.
Huang HL; Leung CY; Saito E; Katanoda K; Hur C; Kong CY; Nomura S; Shibuya K
BMC Med; 2020 Sep; 18(1):257. PubMed ID: 32921305
[TBL] [Abstract][Full Text] [Related]
2. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Kowada A
Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
[TBL] [Abstract][Full Text] [Related]
3. Personalizing age of gastric cancer screening based on comorbidity in China: Model estimates of benefits, affordability and cost-effectiveness optimization.
Qin S; Wang X; Li S; Wu M; Wan X
Prev Med; 2024 Feb; 179():107851. PubMed ID: 38191061
[TBL] [Abstract][Full Text] [Related]
4. Estimated Cost-effectiveness of Endoscopic Screening for Upper Gastrointestinal Tract Cancer in High-Risk Areas in China.
Xia R; Zeng H; Liu W; Xie L; Shen M; Li P; Li H; Wei W; Chen W; Zhuang G
JAMA Netw Open; 2021 Aug; 4(8):e2121403. PubMed ID: 34402889
[TBL] [Abstract][Full Text] [Related]
5. Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study.
Qin S; Wang X; Li S; Tan C; Zeng X; Luo X; Yi L; Peng L; Wu M; Peng Y; Wang L; Wan X
Pharmacoeconomics; 2022 Jul; 40(7):725-737. PubMed ID: 35701687
[TBL] [Abstract][Full Text] [Related]
6. Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
Kregting LM; Sankatsing VDV; Heijnsdijk EAM; de Koning HJ; van Ravesteyn NT
Int J Cancer; 2022 Jul; 151(2):287-296. PubMed ID: 35285018
[TBL] [Abstract][Full Text] [Related]
7. Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study.
Qin S; Wang X; Li S; Tan C; Zeng X; Wu M; Peng Y; Wang L; Wan X
Front Public Health; 2022; 10():955120. PubMed ID: 36033760
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity.
Saumoy M; Schneider Y; Shen N; Kahaleh M; Sharaiha RZ; Shah SC
Gastroenterology; 2018 Sep; 155(3):648-660. PubMed ID: 29778607
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Impact and Cost-Effectiveness of Surveillance of Incidentally Detected Gastric Intestinal Metaplasia: A Microsimulation Analysis.
Thiruvengadam NR; Gupta S; Buller S; Awad I; Gandhi D; Ibarra A; Latorre G; Riquelme A; Kochman ML; Cote G; Shah SC; Saumoy M
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):51-61. PubMed ID: 37302442
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women.
Tina Shih YC; Dong W; Xu Y; Shen Y
Value Health; 2019 Feb; 22(2):185-193. PubMed ID: 30711063
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.
Saito S; Muneoka Y; Ishikawa T; Akazawa K
Clin Ther; 2017 Dec; 39(12):2380-2388. PubMed ID: 29175097
[TBL] [Abstract][Full Text] [Related]
13. International cost-effectiveness analysis evaluating endoscopic screening for gastric cancer for populations with low and high risk.
Ascherman B; Oh A; Hur C
Gastric Cancer; 2021 Jul; 24(4):878-887. PubMed ID: 33595744
[TBL] [Abstract][Full Text] [Related]
14. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis.
Yeh JM; Hur C; Ward Z; Schrag D; Goldie SJ
Gut; 2016 Apr; 65(4):563-74. PubMed ID: 25779597
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
17. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis.
Kapoor R; So JBY; Zhu F; Too HP; Yeoh KG; Yoong JS
Value Health; 2020 Sep; 23(9):1171-1179. PubMed ID: 32940235
[TBL] [Abstract][Full Text] [Related]
19. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
